Association of uric acid levels with the development of metabolic dysfunction-associated and metabolic and alcohol-related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups

被引:0
作者
Fukuda, Tatsuya [1 ,2 ,3 ,4 ]
Akihisa, Taro [2 ,4 ]
Okamoto, Takahiro [1 ]
Fukaishi, Takahiro
Kawakami, Akio [4 ]
Tanaka, Makoto [5 ]
Yamada, Tetsuya [3 ]
Monzen, Koshiro [4 ]
机构
[1] Mirraza Shinjuku Tsurukame Clin, Tokyo 1600022, Japan
[2] Tokyo Metropolitan Okubo Hosp, Dept Endocrinol & Metab, 2-44-1 Kabuki-cho,Shinjyuku ku, Tokyo 1608488, Japan
[3] Inst Sci Tokyo, Grad Sch Med & Dent Sci, Dept Mol Endocrinol & Metab, Tokyo 1138510, Japan
[4] Shinjuku Tsurukame Clin, Tokyo 1510053, Japan
[5] Koganei Tsurukame Clin, Tokyo 1840004, Japan
关键词
Metabolic dysfunction-associated steatotic liver disease (MASLD); Nonalcoholic fatty liver disease (NAFLD); Metabolic and alcohol related/associated liver disease (MetALD); Alcohol consumption; Uric acid; INSULIN-RESISTANCE; HYPERURICEMIA; INDEX; RISK;
D O I
10.1507/endocrj.EJ24-0622
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hyperuricemia reflects increased insulin resistance, and uric acid (UA) may serve as a predictive marker for the development of metabolic dysfunction-associated steatotic liver disease (MASLD); however, few studies have investigated this condition in the Japanese population. Thus, this retrospective observational study aimed to investigate the association of hyperuricemia with the risk of MASLD or metabolic and alcohol-related liver disease (MetALD) in individuals undergoing health checkups. A cross-sectional analysis was performed on 58,110 individuals, dividing them into quartile groups according to UA values for men and women (Q1 being the lowest and Q4 being the highest), and examining the complication rate of MASLD/MetALD. Subsequently, among 22,364 individuals without MASLD/MetALD, the relationship between UA at baseline and MASLD/MetALD development during follow-up was investigated using Cox proportional hazard models. In the cross-sectional analysis, the higher UA group had a higher complication rate of MASLD/MetALD in both men and women. In the follow-up analysis, both genders in the higher UA quartiles had a significantly higher incidence of MASLD/ MetALD than those in the lower quartiles. Multivariate Cox proportional hazards analysis revealed that Q4 had a significantly higher hazard ratio than Q1 for both genders. These trends were the same in the time-dependent body mass index (BMI) model, which incorporated BMI as a time-dependent variable. High UA levels may serve as a predictive marker for MASLD/ MetALD development. UA monitoring during health checkups could enable early detection and provision of intervention, improving patient outcomes.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] The Mediation Effects of Type 2 Diabetes Mellitus and Related Biomarkers on the Association of Metabolic Dysfunction-associated Steatotic Liver Disease and Fibrosis
    Cai, Rujun
    Liu, Zhenqiu
    Fan, Hong
    Zhang, Xin
    Chen, Yizhou
    Zhang, Tiejun
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2025, 34 (01) : 47 - 54
  • [42] Adherence to the planetary health diet index and metabolic dysfunction-associated steatotic liver disease: a cross-sectional study
    Qiu, Xin
    Shen, Shuang
    Jiang, Nizhen
    Lu, Donghong
    Feng, Yifei
    Yang, Guodong
    Xiang, Bangde
    FRONTIERS IN NUTRITION, 2025, 12
  • [43] Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease
    Henin, Guillaume
    Loumaye, Audrey
    Leclercq, Isabelle A.
    Lanthier, Nicolas
    JHEP REPORTS, 2024, 6 (02)
  • [44] Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
    Mellemkjaer, Anders
    Kjaer, Mikkel Breinholt
    Haldrup, David
    Gronbaek, Henning
    Thomsen, Karen Louise
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 28 - 34
  • [45] Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk
    Ionescu, Vlad Alexandru
    Gheorghe, Gina
    Bacalbasa, Nicolae
    Diaconu, Camelia Cristina
    BIOMOLECULES, 2025, 15 (02)
  • [46] Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease
    Li, Fenfen
    Yuan, Ruyan
    Zhang, Jiamin
    Su, Bing
    Qi, Xiaolong
    ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2025, 20 (02)
  • [47] The plasma lipidome varies with the severity of metabolic dysfunction-associated steatotic liver disease
    Heymann, Clement J. F.
    Mak, Anne Linde
    Holleboom, Adriaan G.
    Verheij, Joanne
    Shiri-Sverdlov, Ronit
    van Mil, Saskia W. C.
    Tushuizen, Maarten E.
    Koek, Ger H.
    Grefhorst, Aldo
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [48] Late-Life Metabolic Dysfunction-Associated Steatotic Liver Disease and its Association With Physical Disability and Dementia
    Clayton-Chubb, Daniel
    Kemp, William W.
    Majeed, Ammar
    Woods, Robyn L.
    Ryan, Joanne
    Murray, Anne M.
    Chong, Trevor T. J.
    Lubel, John S.
    Tran, Cammie
    Hodge, Alexander D.
    Schneider, Hans G.
    Mcneil, John J.
    Roberts, Stuart K.
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2024, 79 (04):
  • [49] Pregnancy does not affect liver chemistries in metabolic dysfunction-associated steatotic liver disease
    Finer, Zoe
    Lopez, Christine
    Sharpton, Suzanne
    Gao, Yue
    Lindsell, Christopher
    Lister, Rolanda
    Thompson, Jennifer
    Izzy, Manhal
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (12)
  • [50] Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
    Moon, Joon Ho
    Jeong, Seogsong
    Jang, Heejoon
    Koo, Bo Kyung
    Kim, Won
    ECLINICALMEDICINE, 2023, 65